INTRODUCTION {#sec1-1}
============

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory ailments affecting the elderly and the 4^th^ leading cause of mortality worldwide. With time, the concept of COPD as a disease confined only to the lungs has underwent a radical change, and it is now increasingly recognized as a common preventable and treatable disease with significant extrapulmonary manifestations. The inflammation in COPD is not only confined to the lungs but rather is believed to have systemic spill-over leading to extrapulmonary effects. The extrapulmonary effects or systemic manifestations include cardiovascular disease, osteoporosis, diabetes, lung cancer, weight loss as well as psychiatric comorbidities.

There is increasing evidence that depression and anxiety are important comorbidities in COPD and may influence various facets of COPD and may have bidirectional cause and effect relationship.\[[@ref1]\] There is a paucity of studies regarding both the burden as well as the association of these psychiatric comorbidities in COPD, especially in developing countries where a lack of social support mechanism for the elderly may only aggravate the problem. The present study was planned to assess the association of anxiety and/or depression and COPD in terms of symptom scores, functional capacity, and history of hospitalizations which is a predictor of future exacerbations/hospitalizations and BODE index.

MATERIALS AND METHODS {#sec1-2}
=====================

All consecutive patients of COPD attending the Outpatient Department of AIIMS Rishikesh, diagnosed by history and clinical examination, were screened for the study from August 2014 to September 2015 by chest X-ray, routine hematological, biochemical investigations, and electrocardiography. Spirometry to record forced expiratory volume in 1 s (FEV1) was performed using turbine-based spirometer confirming to the American Thoracic Society (ATS) and European Respiratory Society guidelines to confirm the diagnosis and stage the patients. Patients \>70 years of age and with comorbidities, for example, moderate-to-severe hypertension, diabetes mellitus, ischemic heart disease, chronic liver or renal disease, and any associated significant restrictive lung disease were excluded from the study. Two hundred and fifty patients were screened, and 128 patients consenting for the study were enrolled.

By a detailed questionnaire, baseline parameters were recorded including sociodemographic data, smoking history, any other addictions, and body mass index (BMI). Symptom scores including dyspnea according to Modified Medical Research Council Scale (mMRC) and Clinical COPD Questionnaire (CCQ) -- the Hindi language validated tool for health-related quality of life (HRQoL) were also recorded. Scores on CCQ range from 0 to 60 with higher scores suggestive of poorer quality of life. Functional capacity was assessed by 6-min walk distance (6MWD) according to ATS guidelines. History of hospitalization over the past 1 year and BODE index were also evaluated. All patients were then screened by Hospital Anxiety and Depression Scale (HADS). A cutoff score of ≥8 out of 21 for both depression and anxiety individually was considered. Patients who had more than the cutoff score on HADS were referred for psychiatric evaluation whose diagnosis were then confirmed by a diagnostic interview using the International Classification of Diseases, Tenth Edition Diagnostic Criteria for Research (ICD-10 DCR). The research was approved by the Institute\'s Ethical Committee.

Statistics {#sec2-1}
----------

All statistics were performed using Statistical Package for the Social Sciences 17.0. SPSS 17(IBM). Categorical variables have been described as frequencies, whereas continuous variables have been tested for normality and are presented as mean and standard deviation. Chi-square test and independent sample *t*-test have been used for statistical analysis. *A priori*, a two-sided level of significance was set at *P* \< 0.05.

RESULTS {#sec1-3}
=======

Of the 128 patients eligible for enrollment in the study, 117 (91.4%) were male with a mean age of 61.04 years. Other clinical variable of the whole sample are mentioned in [Table 1](#T1){ref-type="table"}.

###### 

Sociodemographic and clinical variables of the whole sample (*n*=128)
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[Table 2](#T2){ref-type="table"} shows the distribution of psychiatric comorbidities in the sample. A total of 40 (31.3%) had depressive disorder and/or anxiety disorders with depression being most common psychiatric comorbidity.

###### 

Different psychiatric comorbidities with chronic obstructive pulmonary disease\*
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[Table 3](#T3){ref-type="table"} shows the comparison of various sociodemographic and clinical variables in the group of COPD patients with and without psychiatric comorbidities. Both the baseline dyspnea scores (by mMRC) and CCQ scores for QoL were significantly more in patients with psychiatric co-morbidity.

###### 

Comparison of various sociodemographic and clinical variables in the group of chronic obstructive pulmonary disease patients with (*n*=40) and without (*n*=88) psychiatric comorbidities

![](LI-35-31-g003)

Although 6MWD and postbronchodilator FEV1 were lesser in the comorbid group, the difference did not reach statistical significance. There was no significant difference in BMI, the proportion of current smokers, BODE index, and history of hospitalizations/exacerbation between the two groups.

A significant difference in the GOLD classification (based on symptom scores and risk assessment) subcategories between the two groups suggests that a high proportion of patients in the comorbid group belong to the high symptom burden group (80%) irrespective of the risks (low or high), whereas those without comorbidity is underrepresented in the high symptom burden, low-risk group (8%), whereas almost equally represented among the other subgroups. On the other hand, no significant difference was found between the two groups in terms of spirometric classification and postbronchodilator FEV1.

DISCUSSION {#sec1-4}
==========

Anxiety and depression are the most common psychiatric comorbidities associated with COPD. Varying prevalence rates have been reported from various parts of world ranging from 5% to more than 40%\[[@ref2][@ref3][@ref4]\] both because of variation in the study participants to various psychological tools having been used for screening. Among these, HADS has shown to be a reliable and frequently used psychological measurement instrument internationally for COPD patients.\[[@ref5]\] Although there are few studies regarding the prevalence of anxiety and/or depression among COPD patients in India, there is a paucity of studies regarding the impact of these on COPD where both low awareness levels, as well as financial issues, may worsen the situation.

An Indian study among 100 stable patients of COPD using Hindi language translated Patient Health Questionnaire (PHQ-9) found the cumulative prevalence of depression to be 72% and majority of patients were in spirometric stage 2 or 3 (GOLD guidelines).\[[@ref6]\] In another Indian study among 126 stable patients of COPD, 33.3% showed moderate-to-severe depressive symptoms, whereas 20.6% patients had major depressive disorder on PHQ-9 Scale. Educational and occupational status, BMI, FEV1, respiratory symptoms, physical impairment, and dyspnea were found to be potential predictors of depression in COPD patients.\[[@ref7]\] In our study, 31.3% had depression and/or anxiety associated with COPD. Depression was the most common psychiatric comorbidity (22.7%) associated with COPD. As per our study design, all patients were initially screened by HADS, and the diagnosis was then confirmed among screened positive patients by a psychiatrist using ICD 10-DCR. This could account for the lesser prevalence considering our methodology for diagnosis to be comparatively more rigorous.

The association between psychiatric comorbidities and COPD has been evaluated in terms of symptom scores, quality of life, adherence to therapy, risk of hospitalizations, readmissions, mortality, outcomes in rehabilitation, smoking rates, and cognitive decline in different studies. Studies have also evaluated link between medication adherence and adherence to rehabilitation and presence of psychiatric comorbidities.\[[@ref8]\] Moreover, variable scales and variable patient groups have been used in studies world over. Studies in developing countries evaluating the impact of psychiatric comorbidities are far and few.

In a study conducted in China, 701 COPD patients entering pulmonary rehabilitation were assessed using HADS, and it concluded that symptoms of anxiety and/or depression are associated with impaired HRQoL as measured by St. George Respiratory Questionnaire (SGRQ).\[[@ref3]\] Another study among 307 stable COPD reported that symptom scores in terms of COPD assessment test scores (that also evaluates HRQoL) had modest correlation with HADS scores though the study did not find differences in the proportions of patients with clinically relevant symptoms of anxiety and/or depression between GOLD Groups A to D.\[[@ref9]\] Another prospective cohort study among 376 hospitalized patients of COPD concluded by multivariate analyses that depression affects symptoms, activities, and impacts HRQoL as measured by SGRQ at the index hospitalization and 1-year later, even after controlling for confounders (such as chronicity and severity of COPD, comorbidities, and behavioral, psychosocial, and socioeconomic variables). Depression was also significantly associated with mortality, longer index and total hospital stay, and persistent smoking at 6 months.\[[@ref10]\] Some of the differences might have been due to the different sample (hospitalized patients vs. patients enrolled for rehabilitation vs. outpatients) or the tools used for evaluation of HRQoL.

A study among 337 clinically stable COPD patients using SGRQ for assessing HRQoL and HADS concluded by multivariate analyses that anxiety, depression, or both conditions were associated with poor HRQoL for all SGRQ domains.\[[@ref11]\] The INSPIRE-II study enrolled 162 patients and evaluated them using multiple psychosocial test battery including Brief Fatigue Inventory, SGRQ, Shortness of Breath Questionnaire, State-Trait Anxiety Inventory, and Beck Depression Inventory (BDI). It concluded after covariate adjustment that higher anxiety and depression levels were associated with greater levels of fatigue, shortness of breath, and frequency of COPD symptoms\[[@ref12]\] similar to conclusions from our study. Studies evaluating HRQoL using CCQ have also found association with anxiety/depression.\[[@ref13]\] Our study also showed similar results and found patients with psychiatric comorbidities had poorer HRQoL evaluated by CCQ as well as higher symptom scores, both of which are possibly interlinked. Moreover, we also found a large proportion of patients with psychiatric comorbidity to be in GOLD Group B and D (high symptom burden group) as was found in one study\[[@ref14]\] though others found either uniform distribution of this comorbidity in all GOLD Subgroups 9 or overrepresentation in Group D3. A few studies have even reported a totally contradictory result and found no association between anxiety and/or depression and deterioration of QoL\[[@ref15]\] or activity-related dyspnea.\[[@ref16]\]

Possible association between symptoms of depression and current smoking in COPD patients has been demonstrated in few studies.\[[@ref10][@ref17][@ref18]\] Although we found an association with QoL in our study, no significant difference in terms of current smokers was seen between the two groups \[[Table 3](#T3){ref-type="table"}\]. Possible reasons for the latter discrepancy might be due to cultural difference, longitudinal versus cross-sectional study design and inclusion versus exclusion of comorbid medical disorders in the sample, and generally lower rate of psychiatric comorbidity compared to the above studies.

Studies evaluating the association between depression and functional capacity in terms of 6MWD and spirometric variables (FEV1) also throw up conflicting results. In a multicentric cross-sectional study, clinically significant depression was associated with worse quality of life, reduced exercise capacity, greater dyspnea, and a higher score in the BODE index.\[[@ref19]\] Other studies have reported no association between emotional status and exercise tolerance including 6MWD.\[[@ref20][@ref21][@ref22]\] While some studies have reported no association between GOLD staging of COPD and depression,\[[@ref23]\] others have found significant correlation between scores on BDI and FEV1, general health perception, vitality, general mental health, and physical function but no correlation between 6 MWT and emotional status, and quality of life.\[[@ref22]\] A large study done in China reported COPD severity (assessed by ADO index \[age, dyspnea, and airflow obstruction\]) was significantly correlated with anxiety and depression, physical strength, daily living activities, and social activities (evaluated through an indigenously designed comprehensive scale).\[[@ref24]\]

A study from India concluded that as spirometric severity of COPD increases, score on PHQ-9 (that evaluate severity of depressive symptoms) also increases.\[[@ref6]\] Our study shows no significant association between the two and possible reason could be lesser patients of very severe COPD in our enrolled population.

Association between psychiatric comorbidities and hospitalizations, their frequency, mortality, and overall prognosis in terms of indices such as BODE has been an area of active research, and conflicting results have been reported. Few studies have reported association of depression not only with increased symptom burden but also with longer hospitalization stays,\[[@ref17]\] significantly higher risk of exacerbations, costs,\[[@ref25]\] readmissions,\[[@ref26][@ref27]\] poorer prognosis,\[[@ref28]\] and higher risk of death.\[[@ref9]\] In a review, in which 22 cohort studies were included, sixteen of the studies showed that depression was associated with increased mortality and more COPD exacerbations.\[[@ref28]\] A review of English-language peer-reviewed longitudinal and retrospective studies concluded that though some acceptable evidence suggested that psychological distress confers greater risk for exacerbations, more specifically symptom-based exacerbations or those treated in the patient\'s own environment, Most studies showed an absence of a positive association, especially with exacerbations leading to hospitalization.\[[@ref29]\] Similarly, the absence of association between depression and rehospitalization was reported by other studies.\[[@ref30]\] Although our study demonstrated higher hospitalizations in COPD patients with comorbidity than those without [Table 3](#T3){ref-type="table"}, did not reach level of statistical significance. Overall prognosis in terms of BODE index also was not statistically significant between the two groups, unlike other studies.\[[@ref24][@ref31]\]

CONCLUSIONS {#sec1-5}
===========

World-over studies have evaluated widely both the prevalence as well as the impact of depressive and anxiety disorders on the course of COPD. However, the studies from developing countries have been few and mostly focusing on the prevalence of these disorders rather than their impact. Our study has tried to evaluate the association of these disorders with various facets of COPD in terms of symptom scores, quality of life, history of hospitalizations, functional capacity in terms of 6MWD, and overall prognosis in terms of BODE index.

COPD patients with anxiety and/or depressive disorder comorbidities have more symptoms pertaining to dyspnea and poorer quality of life compared to COPD patients without these comorbidities in spite of having similar spirometric variables. In our busy clinical practice screening for depression and/or anxiety, especially in those COPD patients with higher symptom scores and poorer quality of life should atleast be performed.

Our study also has its own limitations in terms of small sample size and inclusion of only stable patients of COPD. Moreover, being a hospital-based study, the prevalence reported here might be higher compared to that in a community-based sample. In addition, our study also has an edge over other studies that not only used HADS as screening tool; diagnosis in screening positive patients was also confirmed by a diagnostic psychiatric interview using ICD 10-DCR increasing the diagnostic accuracy of psychiatric comorbidities.

The presence of depression and/or anxiety leads to poorer quality of life and higher symptom scores. Screening for psychiatric comorbidities should be performed in all COPD patients, especially with higher symptom scores and poorer quality of life.
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